The phase II trial missed its primary endpoint, but the P2Y12 inhibitor seemed to have some advantages over clopidogrel.

The document was simplified to track closer with practical clinical decision-making, says co-chair David Winchester.

The trial bolsters ENCHANTED2/MT and suggests it’s better to not be too aggressive after a mechanical intervention.

As reported by TCTMD, the earlier PROMPT-HF study showed that similar alerts improved GDMT use in the chronic heart failure ...

With no large RCTs to learn from, these international data offer insights into hard outcomes with conduction-system pacing.

It’s time to stop futzing about with single LDL-lowering drugs for high- and very-high-risk patients, says lipid expert ...

The guideline-recommended criteria enable clinically meaningful prediction: adding factors like sex and race will hone ...

If I were to write the guidelines, I would recommend against using it. There is no benefit for this approach,” Tudor Jovin ...

The SGLT1/2 inhibitor joins the two SGLT2 inhibitors already approved for both HFrEF and HFpEF on the US market.

This confirms that clinicians shouldn’t be afraid of starting anticoagulation soon after stroke, a researcher says.

QFR, derived from angiography, might be used to predict which stenoses are likely to matter beyond the acute phase.

The small, pragmatic study, not powered for hard endpoints, does validate ESC recommendations and should prompt change.